Current shingles vaccine linked to lower risk of coronary heart disease, stroke and heart failure
A study published in Nature Medicine suggests that the Shingrix shingles vaccine is associated with a lower risk of cardiovascular issues compared to the older Zostavax vaccine. Researchers analyzed health records of over 36,000 adults aged 60 and older to identify these potential heart-health benefits.
Why it matters
This finding could influence public health vaccination strategies and provide additional incentives for older adults to receive the more effective recombinant shingles vaccine.
edited by Lisa Lock , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Unsplash/CC0 Public Domain Shingles is a painful and serious condition affecting many older people. It is caused by the herpes zoster virus, which can flare up in people who previously had chickenpox. A vaccine against shingles (Zostavax) was introduced in 2006. In many countries, including the U.K. and U.S., Zostavax has now been withdrawn and replaced by a much more effective recombinant vaccine (Shingrix). In the U.K., Shingrix is being offered by the NHS to all older people and certain other groups.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in